cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2013-3-55-57cardiovascular-195Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMАНТАГОНИСТЫ РЕЦЕПТОРОВ АНГИОТЕНЗИНА: В НОГУ СО ВРЕМЕНЕМANGIOTENSIN RECEPTOR ANTAGONISTS: GOING WITH THE TIMESТаратухинЕ. О.TaratukhinE. O.

кардиолог, к. м.н., ассистент кафедры госпитальной терапии № 1 лечебного факультета

tel.: +7 916 637 29 78

cardio03@list.ruГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н. И. Пирогова Минздрава России, МоскваN. I. Pirogov Russian National Medical Research University, Moscow2013200620131235557Copyright © Таратухин Е.О., 20132013Таратухин Е.О.Taratukhin E.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/195

Обзор посвящен блокаторам рецепторов ангиотензина II первого типа как одному из новых и перспективных классов средств, применяемых при артериальной гипертонии. Показано, что кроме собственно антигипертензивного эффекта, эти препараты обладают множеством других преимуществ. Приводится ряд исследований олмесартана как представителя класса, имеющего ярко выраженные дополнительные преимущества, а также результаты его крупных, многоцентровых, рандомизированных испытаний. 

This literature review focuses on the angiotensin II receptor antagonists as one of the new and promising classes of antihypertensive medications. Apart from their antihypertensive activity, these agents possess a number of other beneficial effects. The results of multiple studies, including large multi-centre clinical trials, are presented for olmesartan, an angiotensin receptor antagonist with additional beneficial properties.

артериальная гипертонияметаболический синдромпожилойстарческий возрастолмесартанarterial hypertensionmetabolic syndromeelderly ageolmesartanReferencesMichel MC, Foster C, Brunner HR, et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 2013; 65 (2): 809–48.Michel MC, Foster C, Brunner HR, et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 2013; 65 (2): 809–48.Masanume A, Hamada S, Kikuta K, et al. The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice. Scand J Gastroenterol 2013, Mar 11. OnlineMasanume A, Hamada S, Kikuta K, et al. The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice. Scand J Gastroenterol 2013, Mar 11. OnlineTakada S, Kinugawa S, Hirabayashi K, et al. Angiotensin II Receptor blocker improves the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice. J Appl Physiol 2013; Jan 17. OnlineTakada S, Kinugawa S, Hirabayashi K, et al. Angiotensin II Receptor blocker improves the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice. J Appl Physiol 2013; Jan 17. OnlineIshizuka T, Rozenhal V, Fischer T, et al. Interindividual variability of carboxy methylene butenolidase homolog, a novel olmesartan medoxomil hydrolase, in human liver and intestine. Drug Metab Dispos 2013; Mar 7. OnlineIshizuka T, Rozenhal V, Fischer T, et al. Interindividual variability of carboxy methylene butenolidase homolog, a novel olmesartan medoxomil hydrolase, in human liver and intestine. Drug Metab Dispos 2013; Mar 7. OnlineKosaka S, Pelisch N, Rahman M, et al. Effects of angiotensin II AT 1 receptor blockade on high fat diet — induced vascular oxidative stress and endothelial dysfunction in Dahl salt-sensitive rats. J Pharmacol Sci 2013;121 (2): 95–102.Kosaka S, Pelisch N, Rahman M, et al. Effects of angiotensin II AT 1 receptor blockade on high fat diet — induced vascular oxidative stress and endothelial dysfunction in Dahl salt-sensitive rats. J Pharmacol Sci 2013;121 (2): 95–102.Derosa G, Cicero AF, Carbone A, et al. Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single pill combination compared with olmesartan or amlodipine monotherapies. J Am Soc Hypertens 2013; 7 (1): 32–9.Derosa G, Cicero AF, Carbone A, et al. Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single pill combination compared with olmesartan or amlodipine monotherapies. J Am Soc Hypertens 2013; 7 (1): 32–9.Arao T, Okada Y, Mori H, et al. Antihypertensive and methabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension. Endocr J 2013; Jan 10. OnlineArao T, Okada Y, Mori H, et al. Antihypertensive and methabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension. Endocr J 2013; Jan 10. OnlineIzhawa Y, Ischizawa K, Sakurada T, et al. Angiotensin II receptor blocker improves tumor necrosis factor-alpha induced cytotoxicity via antioxidative effect in human glomerular endothelial cells. Pharmacology 2012; 90: 324–31.Izhawa Y, Ischizawa K, Sakurada T, et al. Angiotensin II receptor blocker improves tumor necrosis factor-alpha induced cytotoxicity via antioxidative effect in human glomerular endothelial cells. Pharmacology 2012; 90: 324–31.Malacco E, Omboni S, Volpe M, et al. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. J Hypertension 2010; 28: 2342–50.Malacco E, Omboni S, Volpe M, et al. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. J Hypertension 2010; 28: 2342–50.Omboni S, Malacco E, Mallion JM, et al. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome. Drugs Aging, 2012; 29: 981–92.Omboni S, Malacco E, Mallion JM, et al. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome. Drugs Aging, 2012; 29: 981–92.Singh S, Pathak K, Ball V. Product development stidies on surface￾adsorbed nano emulsion of olmesartan medoxomil as a capsular dosage form. AAPS PharmSciTech 2012; 13: 1212–21.Singh S, Pathak K, Ball V. Product development stidies on surface￾adsorbed nano emulsion of olmesartan medoxomil as a capsular dosage form. AAPS PharmSciTech 2012; 13: 1212–21.Garcia Ruiz AL, Divison Garrote JA, Garcia-Agua Soier N, et al. Cost-effectiveness analysis of fixed dose antihypertensive drugs. Semergen 2013; 39: 77–84.Garcia Ruiz AL, Divison Garrote JA, Garcia-Agua Soier N, et al. Cost-effectiveness analysis of fixed dose antihypertensive drugs. Semergen 2013; 39: 77–84.de la Sierra A, Volpe M. Olmesartan-based therapies: an effective way to improve blood pressure control and cardiovascular protection. J Hypertens 2013 Mar 31; suppl 1: 13–7.de la Sierra A, Volpe M. Olmesartan-based therapies: an effective way to improve blood pressure control and cardiovascular protection. J Hypertens 2013 Mar 31; suppl 1: 13–7.Ferrario CM, Panjabi S, Buzinec P, et al. Clinical and economic outcomes associated with amlodipine / renin-angiotensin system blocker combinations. Ther Adv Cardiovasc Dis 2013; 7 (1): 27–9.Ferrario CM, Panjabi S, Buzinec P, et al. Clinical and economic outcomes associated with amlodipine / renin-angiotensin system blocker combinations. Ther Adv Cardiovasc Dis 2013; 7 (1): 27–9.de la Sierra A. Difficult-to-control hypertension: effects of olmesartan￾based combination therapies. J Hypertens 2013 Mar 31; suppl 1: 1–2.de la Sierra A. Difficult-to-control hypertension: effects of olmesartan￾based combination therapies. J Hypertens 2013 Mar 31; suppl 1: 1–2.You J, Wu J, Jiang G, et al. Olmesartan attenuates cardiac remodeling through DLL4 / Notch 1 pathway activation pressure overload mice. J Cardiovasc Pharmacol 2013; 61 (2): 142–51.You J, Wu J, Jiang G, et al. Olmesartan attenuates cardiac remodeling through DLL4 / Notch 1 pathway activation pressure overload mice. J Cardiovasc Pharmacol 2013; 61 (2): 142–51.Imazumi S, Miura SI, Yahiro E, et al. Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers. Curr Pharm Des 2012; Nov 21. OnlineImazumi S, Miura SI, Yahiro E, et al. Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers. Curr Pharm Des 2012; Nov 21. OnlineYanagi M, Tamura K, Fujikawa T, et al. The angiotensin II type 1 receptro blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease. Hypertens Res 2013; 36 (3): 262–9.Yanagi M, Tamura K, Fujikawa T, et al. The angiotensin II type 1 receptro blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease. Hypertens Res 2013; 36 (3): 262–9.Chrysant SG, Germino FW, Neutel JM. Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups. Am J Cardiovasc Drugs 2012; 12 (6): 375–89.Chrysant SG, Germino FW, Neutel JM. Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups. Am J Cardiovasc Drugs 2012; 12 (6): 375–89.Saito I, Kario K, Kushiro T, et al. Rationale, study design, baseline characteristics and blood pressure at 16 weeks in the HONEST study. Hypertens Res 2013; 36 (2): 177–82.Saito I, Kario K, Kushiro T, et al. Rationale, study design, baseline characteristics and blood pressure at 16 weeks in the HONEST study. Hypertens Res 2013; 36 (2): 177–82.

The authors declare that there are no conflicts of interest present.